I think it more simple than that.
1. On the take, and more than likely not paying any taxes...
looks like the price will be back to where it was before this RS anyway.
I can hardly wait to unload this piece of garbage.
I think you mean .012. Why is Bruce still a free man ?
sure don't need his brother to tell me something we have all known for far too long now...
just bought some more this a.m. at 3.17 - was worried it would not fill. It did. Got rid of TWTR earlier. ouch.
how ironic that keemobodakine finds the strength to own OIL related stocks. It must go against your foolish belief in man made "global warming". What a struggle for you...
you make a good point. I think though that may even be an optimistic view.
My thought is more the sounds of crickets...
more like 35k/month.
He cleared about 450 last from SCIE. Which again, if the stock were trading at .40-$1 would be great.
However, his inability to create any brand awareness and product sales is disheartening and certainly not worth anywhere near his current compensation package.
exactly - lack of knowledge.
I am out of this POS once I can trade it again.
This Bruce P. is as dishonest and smarmy as they get.
ah - but don't forget - 2014 was supposed to be the year.
SAN DIEGO, CA--(Marketwired - Jun 2, 2015) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today European researchers recently presented a paper at DDW, the world's largest Gastroenterology meeting, held in Washington, D.C. in May. The results of the paper showed the accuracy of the WavSTAT4R Optical Biopsy System exceeded the guideline of 90% Negative Predictive Value (NPV) put forth by the American Society for Gastrointestinal Endoscopy (ASGE). With an overall NPV of 96% across the entire colon and 98% in the recto-sigmoid colon, the WavSTAT4 Optical Biopsy System was found "...to be accurate enough to leave distal colorectal polyps in place without resection or to resect and discard them without pathologic assessment." The paper went on to conclude that the WavSTAT4 system has the potential to reduce costs and risks associated with the redundant removal of certain colorectal polyps.
"These results highlight the key elements of our value proposition- safer for the patient, faster for the doctor or nurse practitioner, and less expensive for the health care system- and provide the clinical validation of our technology," stated Michael Oliver, President and Chief Executive Officer. "With this clinical validation of the economic savings inherent in the reduction of unnecessary pathology costs and patient complications, we now have the necessary proof to begin our sales and marketing activities throughout Europe."
this is actually quite good news. In the "real" investment world this would be up huge and stay up. We'll see, though. won't we...
indeed. That was a great pr too. Had we had any hint of sales and actual agreements that pr would have sent us upward. The lack of respect MO has brought to us is staggering.
uhhhhhh - no. they won't. Thought they did elude to that in their last PR - so maybe they will.
The product is GREAT. The CEO on the other hand - not so much.
I suspect - unfortunately - you may be right. I hope not but, it would seem if the past determines our future, it does not look good.